Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.

@article{Riekse2006EffectOS,
  title={Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.},
  author={Robert G Riekse and Ge Li and Eric C. Petrie and James Ba Leverenz and Darcy Vavrek and Simona Vuletic and John J. Albers and Thomas J. Montine and Virginia M-Y Lee and Michael Lee and Peter Seubert and Douglas R. Galasko and Gerard D. Schellenberg and William R. Hazzard and E. R. Peskind},
  journal={Journal of Alzheimer's disease : JAD},
  year={2006},
  volume={10 4},
  pages={399-406}
}
BACKGROUND Treatment with HMG-CoA reductase inhibitors ("statins") has been variably associated with a reduced risk of Alzheimer's disease (AD) in epidemiologic studies and reduced amyloid-beta (Abeta) deposition in animal models of AD. Putative neuroprotective effects of statins may vary in relation to their ability to penetrate into the central nervous system (CNS). METHODS We measured levels of cerebrospinal fluid (CSF) AD biomarkers following 14 weeks of treatment with simvastatin (a CNS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…